Evidence map›Paper›PMID 35525097›Full record

ReviewRespiratory medicine and research2022

Cardiovascular manifestations secondary to COVID-19: A narrative review.

C Fauvel, A Trimaille, O Weizman, T Pezel, D Mika, V Waldmann, A Cohen, G Bonnet

Open access · bronzeAbstract readReview
In one paragraph

Review in Respiratory medicine and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

C FauvelCardiology Department, Rouen University Hospital, Rouen 76000, France; Division of Cardiovascular Medicine, Wexner Medical Center, The Ohio State University, 410 West 10th Avenue, Columbus, OH 43210, USA. Electronic address: charles.fauvelccf@gmail.com.
A TrimailleDepartment of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg 67000, France.
O WeizmanCardiology Department, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, 54500, France.
T PezelCardiology Department, Lariboisière Hospital, AP-HP, Université de Paris, Paris 75010, France.
D MikaParis-Saclay University, Inserm, UMR-S 1180, Châtenay-Malabry 92296, France.
V WaldmannCardiology Department, Hôpital Européen Georges Pompidou, Université de Paris, Paris 75015, France.
A CohenDepartment of Cardiology, Saint Antoine and Tenon Hospital, AP-HP, INSERM UMRS-ICAN 1166 and Sorbonne University, Paris, France.
G BonnetUniversité de Bordeaux, 33000, France; Service Médico-Chirurgicale de Valvulopathies et Cardiomyopathies, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac 33600, France.
Inserm · FRUniversité Paris Cité · FRHôpital Civil, Strasbourg · FRThe Ohio State University Wexner Medical Center · USUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly, becoming a major threat to global health. In addition to having required the adaptation of healthcare workers for almost 2 years, it has been much talked about, both in the media and among the scientific community. Beyond lung damage and respiratory symptoms, the involvement of the cardiovascular system largely explains COVID-19 morbimortality. In this review, we emphasize that cardiovascular involvement is common and is associated with a worse prognosis, and that earlier detection by physicians should lead to better management. First, direct cardiac involvement will be discussed, in the form of COVID-19 myocarditis, then secondary cardiac involvement, such as myocardial injury, myocardial infarction and arrhythmias, will be considered. Finally, worsening of previous cardiovascular disease as a result of COVID-19 will be examined, as well as long-term COVID-19 effects and cardiovascular complications of COVID-19 vaccines.

Indexed as

COVID-19MyocarditisCOVID-19 VaccinesHumansPandemicsSARS-CoV-2COVID-19 VaccinesCardiovascular systemCOVID-19

Identifiers

PMID35525097
PMCPMC9065692
OpenAlexW4225384255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.